Q4 2025 financial performance
Research and development expense increased to $116.3 million in Q4 2025 from $25.6 million a year earlier, reflecting clinical and pipeline expansion activities. Selling, general and administrative expense rose to $240.0 million from $141.2 million in Q4 2024 as commercial operations scaled. The company reported a net loss of $58.6 million for the quarter, compared with a net loss of $59.4 million in the prior-year period, reflecting higher operating costs offset by materially higher revenue.
Full-year 2025 snapshot
For full-year 2025, Madrigal reported Rezdiffra net sales of $958.4 million, marking the first full year of commercial launch. Quarterly net sales accelerated through the year, rising from $103.3 million in Q4 2024 to $321.1 million in Q4 2025, indicating sustained sequential growth as patient adoption increased.
The company ended 2025 with $988.6 million in cash, cash equivalents, restricted cash and marketable securities, providing liquidity to support ongoing commercialization and pipeline development. Management indicated that capital will continue to be allocated toward expanding the Rezdiffra franchise and advancing combination therapies and next-generation assets.
Commercial traction and market development
The presentation highlighted continued expansion in the treated patient base and diagnosis rates for MASH. The number of patients on Rezdiffra increased steadily through 2024 and 2025, alongside growth in the addressable F2/F3 target population in the United States. The company reported penetration across specialty practices and progress in securing coverage and access through commercial payers.
Rezdiffra remains the first approved therapy in MASH. Management positioned the product as the foundational therapy in F2/F3 disease, with ongoing efforts to expand the treated population through physician education, practice-level care pathway integration, and patient identification initiatives.
Pipeline development and combination strategy
Beyond the commercial franchise, Madrigal outlined an expanding MASH pipeline anchored by Rezdiffra. Key programs include combination approaches with an oral DGAT-2 inhibitor (ervogastat), oral GLP-1 (MGL-2086), and siRNA-based targets, aimed at addressing complementary disease pathways. The company plans to initiate drug–drug interaction studies in 2026 and advance combination studies thereafter, subject to regulatory discussions.
The company is also pursuing potential expansion into compensated MASH cirrhosis (F4c), with outcomes data anticipated in 2027, which could materially expand the addressable patient population.
Operating expenses and balance sheet
Operating expenses increased in 2025 due to expanded clinical development, commercialization investments, and stock-based compensation. Despite continued net losses, the company’s balance sheet remained robust, with liquidity sufficient to fund operations and development programs over the near to medium term.
Sector context and outlook
The MASH treatment market is in an early stage of development, with diagnosis rates and specialist care pathways expanding. Madrigal’s strategy centers on establishing Rezdiffra as a foundational therapy while building combination regimens to address disease heterogeneity over time. The company expects continued growth in Rezdiffra net sales in 2026 as the treated patient base expands and market awareness improves.
Summary
Madrigal Pharmaceuticals reported strong year-on-year growth in Q4 2025 product revenue, driven by rising Rezdiffra adoption, and nearly $1 billion in net sales for the first full year of launch. Operating costs increased alongside commercial and pipeline investments, while liquidity remained strong. The company continues to advance combination strategies and pipeline assets to support longer-term growth in the evolving MASH treatment market.